Strides Pharma’s Slower U.S., Africa Business Drag Down Q3 Earnings: Motilal Oswal

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Motilal Oswal Report

Strides Pharma Science Ltd.’s Q3 FY21 performance came in below estimates due to the Covid-19-related impact on the US.. and Africa business.

Recovery in the other regulated business was led by healthy volume traction. At the strategic level, the company would de-merge its biotech business under Stelis Biopharma Pvt. Ltd. and intends to list this, thereby unlocking value for shareholders.

We cut our earnings estimate by 19%/7%/5% for FY21/FY22/FY23, accounting for weak flu season related demand in the U.S. and slower offtake of medicines related to acute therapies in the Africa business.

Click on the attachment to read the full report:

DISCLAIMER

This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.